{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:57Z","timestamp":1794047457067,"version":"4.8.0"},"reference-count":43,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"6","license":[{"start":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T00:00:00Z","timestamp":1701302400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Between 2011 and 2012, a phase II trial evaluated the use of the RiBVD (rituximab, bendamustine, velcade and dexamethasone) combination as first-line treatment for mantle cell lymphoma (MCL) patients over the age of 65. We have now re-examined the classic prognostic factors, adding an assessment of TP53 mutation status. Patients (N=74; median age 73 years) were treated with the RiBVD combination. Median progression-free survival (mPFS) was 79 months and median overall survival (mOS) was 111 months. TP53 mutation status was available for 54\/74 (73%) patients. TP53 mutations (TP53mt) were found in 12 patients (22.2%). In multivariate analysis, among the prognostic factors (PF) evaluated, only TP53mt and an albumin level (Alb) 3.6 g\/dL were independently associated with a shorter mPFS. A hazard ratio (HR) of 3.16 (1.3-9.9, P=0.014) was obtained for TP53mt versus TP53 wild-type (wt), and 3.6 (1.39-9.5, P=0.009) for Alb &lt;3.6 g\/dL versus Alb \u22653.6 g\/dL. In terms of mOS, multivariate analysis identified three PF: TP53mt (HR: 5.9 [1.77-19.5, P=0.004]), Alb &lt;3.6 g\/dL (HR: 5.2 [1.46- 18.5, P=0.011]), and ECOG=2 (HR: 3.7 [1.31-10.6, P=0.014]). Finally, a score combining TP53 status and Alb distinguished three populations based on the presence of 0, 1, or 2 PF. For these populations, mPFS was 7.8 years, 28 months, and 2.5 months, respectively. Our prolonged follow-up confirmed the efficacy of the RiBVD regimen, comparing it favorably to other regimens. TP53mt and hypoalbuminemia emerge as strong PF that can be easily integrated into prognostic scores for older adult patients with MCL.<\/jats:p>","DOI":"10.3324\/haematol.2023.283724","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T03:40:31Z","timestamp":1701315631000},"page":"1857-1865","source":"Crossref","is-referenced-by-count":4,"title":["Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of &lt;i&gt;TP53&lt;\/i&gt; mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group"],"prefix":"10.3324","volume":"109","author":[{"given":"Sylvain","family":"Carras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Torroja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anouk","family":"Emadali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Montaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Daguindau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Tempescul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Tchernonog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roch","family":"Houot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Dartigeas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Barbieux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selim","family":"Corm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Banos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Fouillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jehan","family":"Dupuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Macro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Fleury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Jardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clementine","family":"Sarkozy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghandi","family":"Damaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Feugier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc Matthieu","family":"Fornecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile","family":"Chabrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Dorvaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krimo","family":"Bouabdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Amorim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reda","family":"Garidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Voillat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Morineau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Pierre","family":"Moles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hacene","family":"Zerazhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Fontan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazid","family":"Arkam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magda","family":"Alexis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Delwail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Pierre","family":"Vilque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loic","family":"Ysebaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Burroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Callanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Le Gouill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9my","family":"Gressin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,11,30]]},"reference":[{"key":"62103","doi-asserted-by":"crossref","unstructured":"Alaggio R, Amador C, Anagnostopoulos I. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36(7):1720-1748.","DOI":"10.1038\/s41375-022-01625-x"},{"key":"62104","doi-asserted-by":"crossref","unstructured":"Swerdlow SH, Campo E, Pileri SA. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127(20):2375-2390.","DOI":"10.1182\/blood-2016-01-643569"},{"key":"62105","doi-asserted-by":"crossref","unstructured":"Nadeu F, Martin-Garcia D, Clot G. Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes. Blood. 2020; 136(12):1419-1432.","DOI":"10.1182\/blood.2020005289"},{"key":"62106","doi-asserted-by":"crossref","unstructured":"Delfau-Larue M-H, Klapper W, Berger F. High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. Blood. 2015; 126(5):604-611.","DOI":"10.1182\/blood-2015-02-628792"},{"key":"62107","doi-asserted-by":"crossref","unstructured":"Eskelund CW, Dahl C, Hansen JW. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017; 130(17):1903-1910.","DOI":"10.1182\/blood-2017-04-779736"},{"key":"62108","doi-asserted-by":"crossref","unstructured":"Mareckova A, Malcikova J, Tom N. ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients. Leuk Lymphoma. 2019; 60(6):1420-1428.","DOI":"10.1080\/10428194.2018.1542144"},{"key":"62109","doi-asserted-by":"crossref","unstructured":"Ferrero S, Rossi D, Rinaldi A. KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. Haematologica. 2020; 105(6):1604-1612.","DOI":"10.3324\/haematol.2018.214056"},{"key":"62110","doi-asserted-by":"crossref","unstructured":"Kluin-Nelemans HC, Hoster E, Hermine O. Treatment of older patients with mantle cell lymphoma (MCL): long-term follow-up of the Randomized European MCL Elderly Trial. J Clin Oncol. 2020; 38(3):248-256.","DOI":"10.1200\/JCO.19.01294"},{"key":"62111","doi-asserted-by":"crossref","unstructured":"Wang ML, Jurczak W, Jerkeman M. Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. N Engl J Med. 2022; 386(26):2482-2494.","DOI":"10.1056\/NEJMoa2201817"},{"key":"62112","doi-asserted-by":"crossref","unstructured":"Greenwell IB, Staton AD, Lee MJ. Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. Cancer. 2018; 124(11):2306-2315.","DOI":"10.1002\/cncr.31328"},{"key":"62113","doi-asserted-by":"crossref","unstructured":"Wang L, Tang G, Medeiros LJ. MYC rearrangement but not extra MYC copies is an independent prognostic factor in patients with mantle cell lymphoma. Haematologica. 2021; 106(5):1381-1389.","DOI":"10.3324\/haematol.2019.243071"},{"key":"62114","unstructured":"Yi S, Yan Y, Jin M. Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma. J Clin Invest. 2022; 132(3):e153283."},{"key":"62115","doi-asserted-by":"crossref","unstructured":"Agarwal R, Chan Y-C, Tam CS. Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. Nat Med. 2019; 25(1):119-129.","DOI":"10.1038\/s41591-018-0243-z"},{"key":"62116","doi-asserted-by":"crossref","unstructured":"Jain P, Dreyling M, Seymour JF, Wang M. High-risk mantle cell lymphoma: definition, current challenges, and management. J Clin Oncol. 2020; 38(36):4302-4316.","DOI":"10.1200\/JCO.20.02287"},{"key":"62117","doi-asserted-by":"crossref","unstructured":"Martin P, Cohen JB, Wang M. Treatment outcomes and roles of transplantation and maintenance rituximab in patients with previously untreated mantle cell lymphoma: results from large real-world cohorts. J Clin Oncol. 2023; 41(3):541-554.","DOI":"10.1200\/JCO.21.02698"},{"key":"62118","doi-asserted-by":"crossref","unstructured":"Gressin R, Daguindau N, Tempescul A. A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma. Haematologica. 2019; 104(1):138-146.","DOI":"10.3324\/haematol.2018.191429"},{"key":"62119","doi-asserted-by":"crossref","unstructured":"Flinn IW, van der Jagt R, Kahl B. First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study. J Clin Oncol. 2019; 37(12):984-991.","DOI":"10.1200\/JCO.18.00605"},{"key":"62120","doi-asserted-by":"crossref","unstructured":"Robak T, Jin J, Pylypenko H. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. Lancet Oncol. 2018; 19(11):1449-1458.","DOI":"10.1016\/S1470-2045(18)30685-5"},{"key":"62121","doi-asserted-by":"crossref","unstructured":"Rummel MJ, Niederle N, Maschmeyer G. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013; 381(9873):1203-1210.","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"62122","doi-asserted-by":"crossref","unstructured":"Yamshon S, Chen GZ, Gribbin C. Nine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma. Blood Adv. 2023; 7(21):6579-6588.","DOI":"10.1182\/bloodadvances.2023010606"},{"key":"62123","doi-asserted-by":"crossref","unstructured":"Klapper W, Hoster E, Determann O. Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network. J Hematop. 2009; 2(2):103-111.","DOI":"10.1007\/s12308-009-0036-x"},{"key":"62124","doi-asserted-by":"crossref","unstructured":"Aukema SM, Hoster E, Rosenwald A. Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network. Blood. 2018; 131(4):417-420.","DOI":"10.1182\/blood-2017-07-797019"},{"key":"62125","doi-asserted-by":"crossref","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ. Revised response criteria for malignant lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2007; 25(5):579-86.","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"62126","doi-asserted-by":"crossref","unstructured":"Fenske TS. Frontline therapy in mantle cell lymphoma: when clinical trial and real-world data collide. J Clin Oncol. 2023; 41(3):452-459.","DOI":"10.1200\/JCO.22.01661"},{"key":"62127","doi-asserted-by":"crossref","unstructured":"Robak T, Huang H, Jin J. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015; 372(10):944-953.","DOI":"10.1056\/NEJMoa1412096"},{"key":"62128","doi-asserted-by":"crossref","unstructured":"Visco C, Chiappella A, Nassi L. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. Lancet Haematol. 2017; 4(1):e15-e23.","DOI":"10.1016\/S2352-3026(16)30185-5"},{"key":"62129","doi-asserted-by":"crossref","unstructured":"Smith MR, Jegede O, Martin P. ECOG-ACRIN E1411 randomized phase 2 trial of bendamustine-rituximab (BR)-based induction followed by rituximab (R) \u00b1 lenalidomide (L) consolidation for mantle cell lymphoma: effect of adding bortezomib to front-line BR induction on PFS. J Clin Oncol. 2021; 39(15 Suppl):7503.","DOI":"10.1200\/JCO.2021.39.15_suppl.7503"},{"key":"62130","doi-asserted-by":"crossref","unstructured":"Hoster E, Dreyling M, Klapper W. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008; 111(2):558-565.","DOI":"10.1182\/blood-2007-06-095331"},{"key":"62131","doi-asserted-by":"crossref","unstructured":"Hoster E, Rosenwald A, Berger F. Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European Mantle Cell Lymphoma Network. J Clin Oncol. 2016; 34(12):1386-1394.","DOI":"10.1200\/JCO.2015.63.8387"},{"key":"62132","doi-asserted-by":"crossref","unstructured":"Gressin R, Caulet-Maugendre S, Deconinck E. Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group. Haematologica. 2010; 95(8):1350-1357.","DOI":"10.3324\/haematol.2009.011759"},{"key":"62133","doi-asserted-by":"crossref","unstructured":"Peyrade F, Jardin F, Thieblemont C. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2011; 12(5):460-468.","DOI":"10.1016\/S1470-2045(11)70069-9"},{"key":"62134","doi-asserted-by":"crossref","unstructured":"Mozas P, Rivero A, Rivas-Delgado A. The Prognostic Nutritional Index (PNI) is an independent predictor of overall survival in older patients with follicular lymphoma. Leuk Lymphoma. 2022; 63(4):903-910.","DOI":"10.1080\/10428194.2021.2010064"},{"key":"62135","doi-asserted-by":"crossref","unstructured":"Akhtar OS, Anampa-Guzman A, Cortese MJ. The Age, Comorbidities and Albumin (ACA) Index is independently associated with overall survival in patients with mantle cell lymphoma (MCL). Blood. 2022; 140(Suppl 1):5160-5161.","DOI":"10.1182\/blood-2022-167826"},{"key":"62136","doi-asserted-by":"crossref","unstructured":"Liu H, Zhang C-L, Feng R. Validation and refinement of the Age, Comorbidities, and Albumin Index in elderly patients with diffuse large B-cell lymphoma: an effective tool for comprehensive geriatric assessment. Oncologist. 2018; 23(6):722-729.","DOI":"10.1634\/theoncologist.2017-0361"},{"key":"62137","doi-asserted-by":"crossref","unstructured":"Shah NN, Castillo-Tokumori F, Whiting J. Frontline treatment approaches in TP53-aberrant mantle cell lymphoma. Leuk Lymphoma. 2023; 64(1):230-233.","DOI":"10.1080\/10428194.2022.2131407"},{"key":"62138","doi-asserted-by":"crossref","unstructured":"Hill HA, Qi X, Jain P. Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis. Blood Adv. 2020; 4(13):2927-2938.","DOI":"10.1182\/bloodadvances.2019001350"},{"key":"62139","doi-asserted-by":"crossref","unstructured":"Campo E, Jaffe ES, Cook JR. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022; 140(11):1229-1253.","DOI":"10.1182\/blood.2022015851"},{"key":"62140","doi-asserted-by":"crossref","unstructured":"Narkhede M, Goyal G, Shea L, Mehta A, Giri S. Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma. Blood Adv. 2022; 6(14):4122-4131.","DOI":"10.1182\/bloodadvances.2022007247"},{"key":"62141","doi-asserted-by":"crossref","unstructured":"Malarikova D, Berkova A, Obr A. Concurrent TP53 and CDKN2A gene aberrations in newly diagnosed mantle cell lymphoma correlate with chemoresistance and call for innovative upfront therapy. Cancers (Basel). 2020; 12(8):2120.","DOI":"10.3390\/cancers12082120"},{"key":"62142","doi-asserted-by":"crossref","unstructured":"Jain P, Zhao S, Lee HJ. Ibrutinib with rituximab in first-line treatment of older patients with mantle cell lymphoma. J Clin Oncol. 2022; 40(2):202-212.","DOI":"10.1200\/JCO.21.01797"},{"key":"62143","doi-asserted-by":"crossref","unstructured":"Le Gouill S, Morschhauser F, Chiron D. Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1\/2 trial. Blood. 2021; 137(7):877-887.","DOI":"10.1182\/blood.2020008727"},{"key":"62144","doi-asserted-by":"crossref","unstructured":"Rodrigues JM, Hassan M, Freiburghaus C. p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma. Br J Haematol. 2020; 191(5):796-805.","DOI":"10.1111\/bjh.17023"},{"key":"62145","doi-asserted-by":"crossref","unstructured":"Stefancikova L, Moulis M, Fabian P. Loss of the p53 tumor suppressor activity is associated with negative prognosis of mantle cell lymphoma. Int J Oncol. 2010; 36(3):699-706.","DOI":"10.3892\/ijo_00000545"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283724\/76378","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283724\/77065","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11359\/76378","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:20Z","timestamp":1794045920000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.283724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,30]]},"references-count":43,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.283724","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,30]]}}}